

Bibliography from INCHES presentation – Health Effects of Mold in Children

- [1] Spengler J, Neas L, Nakai S, et al. Respiratory symptoms and housing characteristics. *Indoor Air* 1994;4:72–82.
- [2] Nevalainen A, Seuri M. Of microbes and men. *Indoor Air* 2005;15(Suppl 9):58–64.
- [3] Portnoy J, Kwak K, Dowling P, et al. Health effects of indoor fungi. *Ann Allergy* 2005;94:313–20.
- [4] Fung F, Hughson W. Health effects of indoor fungal bioaerosol exposure. *Appl Occup Environ Hyg* 2003;18:535–44.
- [5] Bush R, Portnoy J, Saxon A, et al. The medical effects of mold exposure. *J Allergy Clin Immunol* 2006;117(2):326–33.
- [6] Institute of Medicine of the National Academies. *Damp indoor spaces and health*. Washington, DC: The National Academies Press; 2004.
- [7] Kuhn D, Ghannoum M. Indoor mold, toxigenic fungi, and *Stachybotrys Chartarum*: infectious disease perspective. *Clin Microbiol Rev* 2003;16(1):144–72.
- [8] Horner W, Helbling A, Salvaggio J, et al. Fungal allergens. *Clin Microbiol Rev* 1995;8(2):161–79.
- [9] Taskinen T, Hyvarinen A, Meklin T, et al. Asthma and respiratory infections in school children with special reference to moisture and mold problems in the school. *Acta Paediatr* 1999;88:1373–9.
- [10] Halonen M, Stern D, Wright A, et al. *Alternaria* as a major allergen for asthma in children raised in a desert environment. *Am J Respir Crit Care Med* 1997;155:1356–61.
- [11] O'Connor G, Walter M, Mitchell H, et al. Airborne fungi in the homes of children with asthma in low-income urban communities: the Inner-City Asthma Study. *J Allergy Clin Immunol* 2004;114:599–606.
- [12] Eggleston P, Rosenstreich D, Lynn H, et al. Relationship of indoor allergen exposure to skin test sensitivity in inner-city children with asthma. *J Allergy Clin Immunol* 1998;102:563–70.

- [13] Arbes S, Gergen P, Elliott L, et al. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the Third National Health and Nutrition Examination Survey. *J Allergy Clin Immunol* 2005;116:377–83.
- [14] Bush R, Prochnau J. *Alternaria*-induced asthma. *J Allergy Clin Immunol* 2004;113:227–34.
- [15] Bush R, Portnoy J. The role and abatement of fungal allergens in allergic diseases. *J Allergy Clin Immunol* 2001;107:S430–40.
- [16] Bobbitt R, Crandall M, Venkataraman A, et al. Characterization of a population presenting with suspected mold-related health effects. *Ann Allergy* 2005;94:39–44.
- [17] Blackley C. Experimental research on the cause and nature of *Catarrhus Aesitivus* (hay fever or hay asthma). London: Bailliere, Tindal and Cox; 1873. [revised edition, London, Dawson Pall Mall, 1959].
- [18] Cantani V, Ciaschi V. Epidemiology of *Alternaria alternata* allergy: a prospective study of 6840 Italian asthmatic children. *Eur Rev Med Pharmacol Sci* 2004;8:289–94.
- [19] Nelson H, Szefer S, Jacobs J, et al. The relationships among environmental allergen sensitization, allergen exposure, pulmonary function, and bronchial hyperresponsiveness in the Childhood Asthma Management Program. *J Allergy Clin Immunol* 1999;104:775–85.
- [20] Perzanowski M, Sporik R, Squillace S, et al. Association of sensitization to *Alternaria* allergens with asthma among school-age children. *J Allergy Clin Immunol* 1998;101:626–32.
- [21] Sanchez H, Bush R. A review of *Alternaria alternata* sensitivity. *Rev Iberoam Micol* 2001;18:56–9.
- [22] O'Hollaren MT, Yunginger JW, Offord KP, et al. Exposure to an aeroallergen as a possible precipitating factor in respiratory arrest in young patients with asthma. *N Engl J Med* 1991;324(6):359–63.
- [23] Nilsson D, Aas K. Immunological specificity and correlation of diagnostic tests for bronchial allergy to *Cladosporium herbarum*. *Acta Paediatr Scand* 1976;65:33–8.
- [24] Zock J, Jarvis D, Luczynska C, et al. Housing characteristics, reported mold exposure, and asthma in the European Community Respiratory Health Survey. *J Allergy Clin Immunol* 2002;110:285–92.
- [25] Malling H, Dreborg S, Weeke B. Diagnosis and immunotherapy of mold allergy. III. *Allergy* 1986;41:507–19.
- [26] Dreborg S, Agrell B, Foucard T, et al. A double-blind, multicenter immunotherapy trial in children using a purified and standardized *Cladosporium* preparation. *Allergy* 1986;41:131–40.
- [27] Malling H, Dreborg S, Weeke B. Diagnosis and immunotherapy of mould allergy. VI. IgE-mediated parameters during a one-year placebo-controlled study of immunotherapy with *Cladosporium*. *Allergy* 1987;42(4):305–14.
- [28] Horst M, Hejjaoui A, Horst V, et al. Double-blind, placebo-controlled rush immunotherapy with a standardized *Alternaria* extract. *J Allergy Clin Immunol* 1990;85:460–72.
- [29] Cantani A, Businco E, Maglio A. *Alternaria* allergy: a three-year controlled study in children treated with immunotherapy. *Allergol Immunopathol (Madr)* 1988;16(1):1–4.
- [30] Bernardis P, Agnoletto M, Puccinelli P, et al. Injective versus sublingual immunotherapy in *Alternaria tenuis* allergic patients. *J Investig Allergol Clin Immunol* 1996;6(1):55–62.
- [31] Kidon I, See Y, Goh A, et al. Aeroallergen sensitization in pediatric allergic rhinitis in Singapore: is air-conditioning a factor in the tropics? *Pediatr Allergy Immunol* 2004;15:340–3.
- [32] Volovitz B, Osur SL, Bernstein JM, et al. Leukotriene C4 release in upper respiratory mucosa during natural exposure to ragweed in ragweed-sensitive children. *J Allergy Clin Immunol* 1988;82(3 Pt 1):414–8.
- [33] Stark P, Celedon J, Chew G, et al. Fungal levels in the home and allergic rhinitis by 5 years of age. *Environ Health Perspect* 2005;113:1405–9.
- [34] Huang S-W, Giannoni C. The risk of adenoid hypertrophy in children with allergic rhinitis. *Ann Allergy Asthma Immunol* 2001;87:350–5.

- [35] Huang SW. The risk of sinusitis in children with allergic rhinitis. *Allergy Asthma Proc* 2000; 21(2):85-8.
- [36] Wilken JA, Berkowitz R, Kane R. Decrements in vigilance and cognitive functioning associated with ragweed-induced allergic rhinitis. *Ann Allergy Asthma Immunol* 2002;89(4): 372-80.
- [37] Dunleavy RA, Baade LE. Neuropsychological correlates of severe asthma in children 9-14 years old. *J Consult Clin Psychol* 1980;48(2):214-9.
- [38] Bender BG. Cognitive effects of allergic rhinitis and its treatment. *Immunol Allergy Clin North Am* 2005;25(2):301-12. [vi-vii].
- [39] Dykewicz MS, Fineman S. Executive summary of joint task force practice parameters on diagnosis and management of rhinitis. *Ann Allergy Asthma Immunol* 1998;81(5 Pt 2): 463-8.
- [40] Wananukul S, Huiprasert P, Pongprasit P. Eczematous skin reaction from patch testing with aeroallergens in atopic children without atopic dermatitis. *Pediatr Dermatol* 1993; 10(3):209-13.
- [41] Clark R, Adinoff A. Aeroallergen contact can exacerbate atopic dermatitis: patch tests as a diagnostic tool. *J Am Acad Dermatol* 1989;21:863-9.
- [42] Sampson H. The role of "allergy" in atopic dermatitis. *Clin Rev Allergy* 1986;4:125-38.
- [43] Drouet M, Bouillaud E. Anaphylactic reaction to *Aspergillus*. *Allerg Immunol (Paris)* 1996; 28(3):88-9.
- [44] Torricelli R, Johansson S, Withrich B. Ingestive and inhalative allergy to the mushroom *Boletus edulis*. *Allergy* 1997;52(7):747-51.
- [45] Maibach H. Contact urticaria syndrome from mold on salami casing. *Contact Derm* 1995; 32(2):120-1.
- [46] Turner E, Greenberger PA, Sider M. Complexities of establishing an early diagnosis of allergic bronchopulmonary aspergillosis in children. *Allergy Proc* 1989;10(1):63-9.
- [47] McCarthy D, Pepys J. Allergic broncho-pulmonary aspergillosis. Clinical immunology: (2) skin, nasal and bronchial tests. *Clin Allergy* 1971;1:415-32.
- [48] Greenberger P, et al. Allergic bronchopulmonary aspergillosis. In: Adkinson N Jr, Yunginger J, Busse W, editors. *Middleton's allergy principles & practice*, vol 2. 6th edition. Philadelphia: Mosby; 2003. p. 1353-71.
- [49] Knutsen A, Blakeslee N, Manoj R, et al. Allergic bronchopulmonary aspergillosis in a patient with cystic fibrosis: diagnostic criteria when the IgE level is less than 500 IU/ml. *Ann Allergy* 2005;95:488-93.
- [50] Laufer P, Fink J, Bruns W, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. *J Allergy Clin Immunol* 1984;73(1 pt 1):44-8.
- [51] Greenberger PA, Patterson R. Allergic bronchopulmonary aspergillosis and the evaluation of the patient with asthma. *J Allergy Clin Immunol* 1988;81(4):646-50.
- [52] Imbeau S, Cohen M, Reed C. Allergic bronchopulmonary aspergillosis in infants. *Am J Dis Child* 1977;131:1127-30.
- [53] Saini S, Boas S, Jerah A, et al. Allergic bronchopulmonary mycosis to *Fusarium vasinfectum* in a child. *Ann Allergy* 1998;80:377-80.
- [54] Donnelly S, McLaughlin H, Brendin C. Period prevalence of allergic bronchopulmonary mycosis in a regional hospital outpatient population in Ireland 1985-88. *Ir J Med Sci* 1991;160(9):288-90.
- [55] Katzenstein A, Sale S, Greenberger PA. Allergic *Aspergillus* sinusitis: a newly recognized form of sinusitis. *J Allergy Clin Immunol* 1983;72(1):89-93.
- [56] Kuperberg S, Bent J. Allergic fungal sinusitis in the pediatric population. *Arch Otolaryngol Head Neck Surg* 1996;122:1381-4.
- [57] deShazo R, Swain R. Diagnostic criteria for allergic fungal sinusitis. *J Allergy Clin Immunol* 1995;96(1):24-35.
- [58] Marple BF. Allergic fungal rhinosinusitis: current theories and management strategies. *Laryngoscope* 2001;111(6):1006-19.

- [59] Schubert M. Medical treatment of allergic fungal sinusitis. *Ann Allergy* 2000;85:90–101.
- [60] McClay J, Marple B. Allergic fungal sinusitis. 2006. Available at: <http://www.emedicine.com/ent/topic510.htm>.
- [61] McClay J, Marple B, Kapadia L, et al. Clinical presentation of allergic fungal sinusitis in children. *Laryngoscope* 2002;112:565–9.
- [62] Chhabra A, Handa KK, Chakrabarti A, et al. Allergic fungal sinusitis: clinicopathological characteristics. *Mycoses* 1996;39(11–12):437–41.
- [63] Muntz H. Allergic fungal sinusitis in children. *Otolaryngol Clin North Am* 1996;29(1):185–92.
- [64] Fan L. Hypersensitivity pneumonitis in children. *Curr Opin Pediatr* 2002;14:323–6.
- [65] Greenberger PA. Mold-induced hypersensitivity pneumonitis. *Allergy Asthma Proc* 2004;25(4):219–23.
- [66] Chiron C, Gaultier C, Boule M, et al. Lung function in children with hypersensitivity pneumonitis. *Eur J Respir Dis* 1984;65:79–91.
- [67] Fink JN, Schlueter DP, Sosman AJ, et al. Clinical survey of pigeon breeders. *Chest* 1972;62(3):277–81.
- [68] Ratjen F, Costabel U, Griese M, et al. Bronchoalveolar lavage fluid findings in children with hypersensitivity pneumonitis. *Eur Respir J* 2003;21:144–8.
- [69] Aebischer CC, Frey U, Schoni MH. Hypersensitivity pneumonitis in a five-year-old boy: an unusual antigen source. *Pediatr Pulmonol* 2002;33(1):77–8.
- [70] O'Connell EJ, Zora JA, Gillespie DN, et al. Childhood hypersensitivity pneumonitis (farmer's lung): four cases in siblings with long-term follow-up. *J Pediatr* 1989;114(6):995–7.
- [71] Jacobs R, Thorner R, Holcomb J, et al. Hypersensitivity pneumonitis caused by *Cladosporium* in an enclosed hot-tub area. *Ann Intern Med* 1986;105(2):204–6.
- [72] Hogan MB, Patterson R, Pore RS, et al. Basement shower hypersensitivity pneumonitis secondary to *Epicoccum nigrum*. *Chest* 1996;110(3):854–6.
- [73] Lee S-K, Kim S-S, Nahm D-H, et al. Hypersensitivity pneumonitis caused by *Fusarium napiforme* in a home environment. *Allergy* 2000;55:1190–3.
- [74] Sugiyama K, Mukae H, Ishii H, et al. Familial summer-type hypersensitivity pneumonitis—case report and review of literature. *Nihon Kokyuki Gakkai Zasshi* 2005;43(11):683–8.
- [75] Iyori J, Kawamura K, Seo K. Summer-type hypersensitivity pneumonitis in a child. *Acta Paediatr Jpn* 1991;33(4):488–91.
- [76] Roeder A, Kirschning CJ, Rupec RA, et al. Toll-like receptors and innate antifungal responses. *Trends Microbiol* 2004;12(1):44–9.
- [77] Roeder A, Kirschning CJ, Rupec RA, et al. Toll-like receptors as key mediators in innate antifungal immunity. *Med Mycol* 2004;42(6):485–98.
- [78] Marodi L. Innate cellular immune responses in newborns. *Clin Immunol* 2006;118(2–3):137–44.
- [79] Wan G-H, Li C-S, Guo S-P, et al. An airborne mold-derived product, β -1,3-D-glucan, potentiates airway allergic responses. *Eur J Immunol* 1999;29:2491–7.
- [80] Hohl T, Van Epps H, Rivera A, et al. *Aspergillus fumigatus* triggers inflammatory responses by stage-specific β -glucan display. *PLoS Pathog* 2005;1:232–40.
- [81] Fogelmark B, Goto H, Yuasa K, et al. Acute pulmonary toxicity of inhaled β -1,3-glucan and endotoxin. *Agents Actions* 1992;35(1–2):50–6.
- [82] Holt P. Potential role of environmental factors in the etiology and pathogenesis of atopy: a working model. *Environ Health Perspect* 1999;107(Suppl 3):485–7.
- [83] Thorn J, Beijer L, Rylander R. Effects after inhalation of (1 \rightarrow 3)- β -D-glucan in healthy humans. *Mediators Inflamm* 2001;10:173–8.
- [84] Beijer L, Thorn J, Rylander R. Effects after inhalation of (1 \rightarrow 3)- β -D-glucan and relation to mould exposure in the home. *Mediators Inflamm* 2002;11(3):149–53.
- [85] Beijer L, Thorn J, Rylander R. Mould exposure at home relates to inflammatory markers in blood. *Eur Respir J* 2003;21:317–92.

- [86] Hirvonen MR, Huttunen K, Roponen M. Bacterial strains from moldy buildings are highly potent inducers of inflammatory and cytotoxic effects. *Indoor Air* 2005;15(Suppl 9): 65–70.
- [87] Douwes J. (1 → 3)-β-D-glucans and respiratory health: a review of the scientific evidence. *Indoor Air* 2005;15:160–9.
- [88] Kheradmand F, Kiss A, Xu J, et al. A protease-activated pathway underlying Th cell type 2 activation and allergic lung disease. *J Immunol* 2002;169(10):5904–11.
- [89] Kauffman HF, Tomec JF, van de Riet MA, et al. Protease-dependent activation of epithelial cells by fungal allergens leads to morphologic changes and cytokine production. *J Allergy Clin Immunol* 2000;105(6 Pt 1):1185–93.
- [90] Johanning E, Biagini R, Hull D, et al. Health and immunology study following exposure to toxigenic fungi (*Stachybotrys chartarum*) in a water-damaged office environment. *Int Arch Occup Environ Health* 1996;68(4):207–18.
- [91] Hodgson MJ, Morey P, Leung WY, et al. Building-associated pulmonary disease from exposure to *Stachybotrys chartarum* and *Aspergillus versicolor*. *J Occup Environ Med* 1998;40(3):241–9.
- [92] Burge HA. Fungi: toxic killers or unavoidable nuisances? *Ann Allergy Asthma Immunol* 2001;87(6 Suppl 3):52–6.
- [93] Etzel RA. Mycotoxins. *JAMA* 2002;287(4):425–7.
- [94] Robbins CA, Swenson LJ, Nealley ML, et al. Health effects of mycotoxins in indoor air: a critical review. *Appl Occup Environ Hyg* 2000;15(10):773–84.
- [95] Page EH, Trout DB. The role of *Stachybotrys* mycotoxins in building-related illness. *AIHAJ* 2001;62(5):644–8.
- [96] Hardin BD, Kelman BJ, Saxon A. Adverse human health effects associated with molds in the indoor environment. *J Occup Environ Med* 2003;45(5):470–8.
- [97] Montalbano M, Lemanske R. Infections and asthma in children. *Curr Opin Pediatr* 2002; 14(3):334–7.
- [98] Kelman BJ, Robbins CA, Swenson LJ, et al. Risk from inhaled mycotoxins in indoor office and residential environments. *Int J Toxicol* 2004;23(1):3–10.
- [99] Jarvis BB, Miller JD. Mycotoxins as harmful indoor air contaminants. *Appl Microbiol Biotechnol* 2005;66(4):367–72.
- [100] Etzel RA, Montana E, Sorenson WG, et al. Acute pulmonary hemorrhage in infants associated with exposure to *Stachybotrys atra* and other fungi. *Arch Pediatr Adolesc Med* 1998;152(8):757–62.
- [101] Centers for Disease Control. Update: pulmonary hemorrhage/hemosiderosis among infants—Cleveland, Ohio, 1993–1996. *MMWR Morb Mortal Wkly Rep* 1997;46(2):33–5.
- [102] Dearborn DG, Smith PG, Dahms BB, et al. Clinical profile of 30 infants with acute pulmonary hemorrhage in Cleveland. *Pediatrics* 2002;110(3):627–37.
- [103] Elidemir O, Colasurdo GN, Rossmann SN, et al. Isolation of *Stachybotrys* from the lung of a child with pulmonary hemosiderosis. *Pediatrics* 1999;104(4 Pt 1):964–6.
- [104] Etzel RA. *Stachybotrys*. *Curr Opin Pediatr* 2003;15(1):103–6.
- [105] Yike I, Dearborn DG. Pulmonary effects of *Stachybotrys chartarum* in animal studies. *Adv Appl Microbiol* 2004;55:241–73.
- [106] Yike I, Rand TG, Dearborn DG. Acute inflammatory responses to *Stachybotrys chartarum* in the lungs of infant rats: time course and possible mechanisms. *Toxicol Sci* 2005;84(2): 408–17.
- [107] Fung F, Clark RF. Health effects of mycotoxins: a toxicological overview. *J Toxicol Clin Toxicol* 2004;42(2):217–34.
- [108] Belson MG, Schier JG, Patel MM. Case definitions for chemical poisoning. *MMWR Recomm Rep* 2005;54(RR-1):1–24.
- [109] Trout DB, Seltzer JM, Page EH, et al. Clinical use of immunoassays in assessing exposure to fungi and potential health effects related to fungal exposure. *Ann Allergy Asthma Immunol* 2004;92(5):483–91 [quiz: 492–4, 575].

- [110] Gilbert J, Brereton P, MacDonald S. Assessment of dietary exposure to ochratoxin A in the UK using a duplicate diet approach and analysis of urine and plasma samples. *Food Addit Contam* 2001;18(12):1088–93.
- [111] Meko FA, Turner PC, Ashcroft AE, et al. Development of a urinary biomarker of human exposure to deoxynivalenol. *Food Chem Toxicol* 2003;41(2):265–73.
- [112] Von Essen S, Robbins RA, Thompson AB, et al. Organic dust toxic syndrome: an acute febrile reaction to organic dust exposure distinct from hypersensitivity pneumonitis. *J Toxicol Clin Toxicol* 1990;28(4):389–420.
- [113] Rask-Andersen A. Organic dust toxic syndrome among farmers. *Br J Ind Med* 1989;46(4):233–8.
- [114] Brinton WT, Vastbinder EE, Greene JW, et al. An outbreak of organic dust toxic syndrome in a college fraternity. *JAMA* 1987;258(9):1210–2.
- [115] Latge JP, Calderone R. Host-microbe interactions: fungi invasive human fungal opportunistic infections. *Curr Opin Microbiol* 2002;5(4):355–8.
- [116] Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. *Clin Microbiol Infect* 2001;7(Suppl 2):8–24.
- [117] Weems JJ Jr, Davis BJ, Tablan OC, et al. Construction activity: an independent risk factor for invasive aspergillosis and zygomycosis in patients with hematologic malignancy. *Infect Control* 1987;8(2):71–5.
- [118] Perraud M, Piens MA, Nicoloyannis N, et al. Invasive nosocomial pulmonary aspergillosis: risk factors and hospital building works. *Epidemiol Infect* 1987;99(2):407–12.
- [119] Krasinski K, Holzman RS, Hanna B, et al. Nosocomial fungal infection during hospital renovation. *Infect Control* 1985;6(7):278–82.
- [120] Buffington J, Reporter R, Lasker BA, et al. Investigation of an epidemic of invasive aspergillosis: utility of molecular typing with the use of random amplified polymorphic DNA probes. *Pediatr Infect Dis J* 1994;13(5):386–93.
- [121] Sehulster L, Chinn RY. Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). *MMWR Recomm Rep* 2003;52(RR-10):1–42.
- [122] Shusterman D. Toxicology of nasal irritants. *Curr Allergy Asthma Rep* 2003;3:258–65.
- [123] Veronesi B, Oortgiesen M. Neurogenic inflammation and particulate matter (PM) air pollutants. *Neurotoxicology* 2001;22:795–810.
- [124] Widdicombe J. Afferent receptors in the airways and cough. *Respir Physiol* 1998;114:5–15.
- [125] Cometto-Muniz J, Cain W. Physicochemical determinants and functional properties of the senses of irritation and smell. In: Gammage R, Berven B, editors. *Indoor air and human health*. 2nd edition. New York: CRC Press; 1996. p. 53–65.
- [126] Nilsson A, Kihlstrom E, Lagesson V, et al. Microorganisms and volatile organic compounds in airborne dust from damp residences. *Indoor Air* 2004;14:74–82.
- [127] Saijo Y, Kishi R, Sata F, et al. Symptoms in relation to chemicals and dampness in newly built dwellings. *Int Arch Occup Environ Health* 2004;77:461–70.
- [128] Laumbach R, Kipen H. Bioaerosols and sick building syndrome: particles, inflammation, and allergy. *Curr Opin Allergy Clin Immunol* 2005;5:135–9.
- [129] Straus D, Cooley J, Wong W, et al. Studies on the role of fungi in sick building syndrome. *Arch Environ Health* 2003;58(8):475–8.
- [130] Wilson S, Straus D. The presence of fungi associated with sick building syndrome in North American zoological institutions. *J Zoo Wildl Med* 2002;33(4):322–7.
- [131] Cooley J, Wong W, Jumper C, et al. Correlation between the prevalence of certain fungi and sick building syndrome. *Occup Environ Med* 1998;55:579–84.
- [132] Baldo JV, Ahmad L, Ruff R. Neuropsychological performance of patients following mold exposure. *Appl Neuropsychol* 2002;9(4):193–202.
- [133] Handal G, Leiner MA, Cabrera M, et al. Children symptoms before and after knowing about an indoor fungal contamination. *Indoor Air* 2004;14(2):87–91.
- [134] Khalili B, Bardana E. International mold toxicity: fact or fiction? A clinical review of 50 cases. *Ann Allergy* 2005;95:239–46.

- [135] Khalili B, Montanaro M, Bardana E. Indoor mold and your patient's health: from suspicion to confirmation. *J Respir Dis* 2005;26(120):520-5.
- [136] Platt S, Martin C, Hunt S, et al. Damp housing, mould growth and symptomatic health state. *Br Med J* 1989;298:1673-8.
- [137] Dalcs R, Zwanzenberg H, Burnctt R, et al. Respiratory health effects of home dampness and molds among Canadian children. *Am J Epidemiol* 1991;134:196-203.
- [138] Brunekreef B, Dockery D, Speizer F, et al. Home dampness and respiratory morbidity in children. *Am Rev Respir Dis* 1989;140:1363-7.
- [139] Hynes P, Brugge D, Osgood N, et al. Investigations into the indoor environment and respiratory health in Boston public housing. *Rev Environ Health* 2004;19(3-4):271-89.
- [140] Horner W. The damp building effect: understanding needed, not more debate. *Ann Allergy* 2005;94:213-5.
- [141] Dekker C, Dales R, Bartlett S, et al. Childhood asthma and the indoor environment. *Chest* 1991;100:922-6.
- [142] Li C-S, Hsu L-Y. Home dampness and childhood respiratory symptoms in a subtropical climate. *Arch Environ Health* 1996;51(1):42-6.
- [143] Yang C-Y, Cheng M-F, Tsai S-S, et al. Effects of indoor environmental factors on risk for acute otitis media in a subtropical area. *J Toxicol Environ Health A* 1999;56:111-9.
- [144] Strachan D, Elton R. Relationship between respiratory morbidity in children and the home environment. *Fam Pract* 1986;3(3):137-42.
- [145] Jedrychowski W, Flak E. Separate and combined effects of the outdoor and indoor air quality on chronic respiratory symptoms adjusted for allergy among preadolescent children. *Int J Occup Med Environ Health* 1998;11(1):19-35.
- [146] Peat JK, Dickerson J, Li J. Effects of damp and mould in the home on respiratory health: a review of the literature. *Allergy* 1998;53(2):120-8.
- [147] Jaakkola J, Jaakkola N, Ruotsalainen R. Home dampness and molds as determinants of respiratory symptoms and asthma in pre-school children. *J Expo Anal Environ Epidemiol* 1993;3(Suppl 1):129-42.
- [148] Strachan D, Sanders C. Damp housing and childhood asthma; respiratory effects of indoor air and temperature and relative humidity. *J Epidemiol Community Health* 1989;43:7-14.
- [149] Bornehag C, Blomquist G, Gyntelberg F, et al. Dampness in buildings and health. *Indoor Air* 2001;11:72-86.
- [150] Santilli J. Health effects of mold exposure in public schools. *Curr Allergy Asthma Rep* 2002;2:460-7.
- [151] Rylander R, Norrhall M, Engdahl U, et al. Airways inflammation, atopy, and (1 → 3)-β-D-glucan. *Am J Respir Crit Care Med* 1998;158:1685-7.
- [152] Meklin T, Husman T, Vepsalainen M, et al. Indoor air microbes and respiratory symptoms of children in moisture damaged and reference schools. *Indoor Air* 2002;12:175-83.
- [153] Meklin T, Potus T, Pekkanen J, et al. Effects of moisture-damage repairs on microbial exposure and symptoms in schoolchildren. *Indoor Air* 2005;15(Suppl 10):40-7.
- [154] Savilahi R, Uitti J, Laippala P, et al. Respiratory morbidity among children following renovation of a water-damaged school. *Arch Environ Health* 2000;55(6):405-10.
- [155] Savilahi R, Uitti J, Roto P, et al. Increased prevalence of atopy among children exposed to mold in a school building. *Allergy* 2001;56(2):175-9.
- [156] Meyer H, Wurtz H, Suadicani P, et al. Molds in floor dust and building-related symptoms in adolescent school children. *Indoor Air* 2004;14:65-72.
- [157] Meyer H, Wurtz H, Suadicani P, et al. Molds in floor dust and building-related symptoms among adolescent school children: a problem for boys only? *Indoor Air* 2005;15(Suppl 10):17-24.
- [158] Scheel C, Rosing W, Farone A. Possible sources of sick building syndrome in a Tennessee middle school. *Arch Environ Health* 2001;56(5):413-9.
- [159] Bartlett K, Kennedy S, Brauer M, et al. Evaluation and a predictive model of airborne fungal concentrations in school classrooms. *Ann Occup Hyg* 2004;48(6):547-54.